New AI-based Technologies in Nuclear Medicine
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorAzienda USL Reggio Emilia - IRCCS
About this trial
The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring. It also investigates the correlation between extravasation and SUV correction in PET/CT diagnostics, providing an estimate of the correction factor necessary for accurate SUV evaluation in case of an extravasation event.
Eligibility criteria
Qualifiers
patients undergoing PET/CT scans or therapeutic treatments with radiopharmaceuticals labelled with alpha or beta emitting nuclides
Disqualifiers
patients whose clinical or psychological conditions do not allow for their involvement
Trial design
Treatments tested in this trial
- RadEye SPRD-ER device: spectrometric radiation detector capable of detecting gamma radiation.
Treatment groups
1,500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov